Published in
Springer (part of Springer Nature), Cancer Chemotherapy and Pharmacology, 4(83), p. 743-753, 2019
DOI: 10.1007/s00280-018-03765-3
Links
Tools
A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer
Journal article published in 2019 by
M. Campone,
T. Bachelot,
F. Penault-Llorca,
A. Pallis,
V. Agrapart,
M. J. Pierrat,
C. Poirot,
F. Dubois,
L. Xuereb,
C. J. Bossard,
N. Guigal-Stephan,
B. Lockhart,
F. Andre 
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 